Close Menu

NEW YORK – China's National Medical Products Administration (NMPA) recently extended approval of the Roche Cobas EGFR Mutation Test v2 to include the use of plasma samples for the detection of EGFR mutations in patients with non-small cell lung cancer, according to a Roche spokesperson.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.